Rationale and design of a randomized controlled trial evaluating whole muscle exercise training effects in outpatients with pulmonary arterial hypertension (WHOLEi+12)

Loading...
Thumbnail Image
Identifiers

Publication date

Authors

Sanchís-Gomar, Fabián
González-Sáiz, Laura
Sanz Ayan, Paz
Fiuza Luces, María del Carmen
Quezada Loaiza, Carlos A.

Advisors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics

Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

Physical exercise is an important component in the management of pulmonary artery hypertension (PAH). The aim of this randomized controlled trial (RCT) is to determine the effects of an 8-week intervention combining muscle resistance, aerobic and inspiratory pressure load exercises in PAH outpatients. The RCT will be conducted from September 2015 to September 2016 following the recommendations of the Consolidated Standards of Reported Trials (CONSORT), with a total sample size of n ≥ 48 (≥24 participants/group). We will determine the effects of the intervention on: (i) skeletal-muscle power and mass (primary end points); and (ii) NT-proBNP, cardiopulmonary exercise testing variables (VO2peak, ventilatory equivalent for CO2 at the anaerobic threshold (VE/VCO2 at the AT), end-tidal pressure of CO2 at the anaerobic threshold (PETCO2 at the AT), 6-min walking distance (6MWD), maximal inspiratory pressure (PImax), health-related quality of life (HRQoL), objectively-assessed spontaneous levels of physical activity, and safety (secondary end points). This trial will provide insight into biological mechanisms of the disease and indicate the potential benefits of exercise in PAH outpatients, particularly on muscle power.

Description

Keywords

Bibliographic reference

Sanchís-Gomar, F., González-Saiz, L., Sanz-Ayan, P., Fiuza-Luces, C., Quezada-Loaiza, C. A., Flox-Camacho, A., ... & Lucía, A. (2015). Rationale and design of a randomized controlled trial evaluating whole muscle exercise training effects in outpatients with pulmonary arterial hypertension (WHOLEi+12). Cardiovascular Drugs and Therapy, [Epub ahead of print].

Type of document